Researchers from Virginia Tech University (VT) have developed a variant of the compound alphaCT1, which can improve heart attack recovery if administered during, or soon after, a heart attack.
19 August 2019 News
18 July 2019 Comment
Forxiga is indicated for monotherapy and combination therapy use to improve glycemic control with the additional benefits of weight loss and blood pressure reduction.
17 June 2019 Comment
Amarin’s Vascepa, AstraZeneca’s Epanova theoretical cardiovascular risk reduction class effect possibly stifled
Although Amarin’s Vascepa (icosapent ethyl) is likely to lock in US Food and Drug Administration approval and swift uptake in cardiovascular disease (CVD) risk reduction, there could be future competition...
23 April 2019 pressreleases
Creative Pharma Services attended the Hellenic Society for Pharmaceutical Management on 18 April.
27 March 2019 Comment
Abbott’s MagLev pump technology is thought to be responsible for the reduction of many severe complications of end-stage heart failure treatment.
25 March 2019 Comment
Minimally invasive interventions for treating peripheral artery disease (PAD) are growing as they continue to demonstrate better patient outcomes compared to pharmaceutical treatment and open surgery.
14 March 2019 News
Researchers from the Stanford University School of Medicine have discovered that AMPK activators, which include metformin for type 2 diabetes, could mitigate the cardiac side effects of chemotherapy drug trastuzumab.